Literature DB >> 9211998

Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Radiation Therapy Oncology Group.

A K Choucair1, C Scott, R Urtasun, D Nelson, B Mousas, W Curran.   

Abstract

UNLABELLED: With increasingly aggressive neurosurgical and radiation therapy modalities (gamma knife, external beam stereotactic radiation and interstitial brachytherapy with or without hyperthermia) offered to patients with malignant astrocytomas (MA), increasing national demand for medical outcome studies and rising health care costs amidst public, business, and governmental debate to cut spending, we as physicians are obligated to continue our research to find effective treatments for malignant astrocytoma (MA) and a cost-effective means to study their impact upon the patient's quality of life (QOL).
PURPOSE: We report data that was collected within the Radiation Therapy Oncology Group (RTOG) on 126 patients with MA who were enrolled in RTOG 91-14. This study was undertaken to prospectively test the feasibility of performing quality of life (QOL) and neuropsychological evaluation (NPE) and collecting this data within the RTOG.
RESULTS: The NPE and QOL parameters that were used in this study are cost effective. They are not only much cheaper than formal cognitive and memory testing, but also provide additional information regarding the patients' day to day functional abilities that are not provided by the current routinely used means, such as KPS. The Mini-Mental Status Exam (MMSE) provides greater sensitivity to patients' differences in neurological status and may be preferable to NFS as an eligibility criteria.

Entities:  

Mesh:

Year:  1997        PMID: 9211998     DOI: 10.1016/s0360-3016(97)00223-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  The use of a simple Likert scale to measure quality of life in brain tumor patients.

Authors:  M P Rogers; J Orav; P M Black
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  Facets and determinants of quality of life in patients with recurrent high grade glioma.

Authors:  A R Giovagnoli; A Silvani; E Colombo; A Boiardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

3.  Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

Authors:  Paul D Brown; Karla V Ballman; Teresa A Rummans; Matthew J Maurer; Jeff A Sloan; Bradley F Boeve; Lalit Gupta; David F Tang-Wai; Robert M Arusell; Matthew M Clark; Jan C Buckner
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

4.  Brain tumours in Sweden 1996: care and costs.

Authors:  P Blomqvist; J Lycke; P Strang; H Törnqvist; A Ekbom
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

5.  Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.

Authors:  Edward A Neuwelt; Paul E Guastadisegni; Péter Várallyay; Nancy D Doolittle
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

6.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 7.  Health-related quality of life in patients with high-grade glioma.

Authors:  Jin-xiang Cheng; Xiang Zhang; Bo-Lin Liu
Journal:  Neuro Oncol       Date:  2008-07-15       Impact factor: 12.300

Review 8.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

10.  Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Andre A Konski; Kathryn Winter; Bernard F Cole; Kie-Kian Ang; Karen K Fu
Journal:  Head Neck       Date:  2009-02       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.